Admera

Admera Health is a next-generation molecular diagnostics company focused on precision medicine and digital health, located in New Jersey, the pharmaceutical hub of the United States. It was originally the clinical testing division of GENEWIZ (Genewiz), a global genomics services company, and spun off to operate independently by mid-2014 with strong support from YuanSheng Ventures, Puyuan Capital, and GENEWIZ (Genewiz). Since its establishment, Admera Health has experienced rapid business growth and emerged as a standout in the highly competitive fields of precision medicine and digital health. In less than two years, five of its next-generation molecular diagnostic products received dual accreditation from CLIA (Clinical Laboratory Improvement Amendments) and CAP (College of American Pathologists) in the U.S., and it has provided high-quality precision medical testing services to nearly 10,000 American patients.Admera Health boasts a robust and efficient R&D team that has developed a series of industry-leading technologies in areas such as pharmacogenomics, cardiovascular diseases, oncology, and digital health. These include the recently CLIA-certified liquid biopsy technology BEST with a detection limit of 0.005%, the fully automated online genomic data clinical analysis and interpretation system AGIS, and market-released products like PGxOne for pharmacogenomic testing, OncoGxOne and OncoGxSelect for cancer genomic testing, and CardioGxOne for cardiovascular disease testing. Based on these achievements, Admera Health was awarded the "2016 North America Frost & Sullivan Technology Innovation Award."